Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jeff Whitten"'
Autor:
Alice T. Shaw, J. Jean Cui, Robert C. Doebele, David M. Hyman, Shanna Stopatschinskaja, John K. Lim, Jeff Whitten, Juliet Liu, Evan Rogers, Zhongdong Huang, Wei Deng, Dayong Zhai, Judy Nguyen, D. Ross Camidge, Myung-Ju Ahn, Viola W. Zhu, Jessica J. Lin, Jeeyun Lee, Dong-Wan Kim, Byoung Chul Cho, Sai-Hong Ignatius Ou, Alexander Drilon
all supplementary files
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb5414f1930e0247c2f633d7f46df3d
https://doi.org/10.1158/2159-8290.22531802.v1
https://doi.org/10.1158/2159-8290.22531802.v1
Autor:
Jeeyun Lee, Byoung Chul Cho, Dayong Zhai, Wei Deng, David M. Hyman, Judy Nguyen, Myung-Ju Ahn, Juliet Liu, Dong Wan Kim, Viola W. Zhu, J. Jean Cui, Jeff Whitten, Alice T. Shaw, Shanna Stopatschinskaja, Robert C. Doebele, Zhongdong Huang, Sai-Hong Ignatius Ou, Jessica J. Lin, Evan Rogers, Alexander Drilon, D. Ross Camidge, John K.C. Lim
Publikováno v:
Cancer Discovery. 8:1227-1236
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA–C can result in significant clinical benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1–3 rearrangements; however, resistance invariably devel